Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AFFYMETRIX (AFFX) -- Ignore unavailable to you. Want to Upgrade?

To: Bill Holtzman who wrote (1441)	1/5/2001 1:04:26 PM
From: BradleyMarshall	Respond to of 1728

Affx has certainly held up well over the last two months. Partially that's due to good news, ie turning profitable and winning a patent dispute. However, many big pharmas have held up well, too, because they're defensive stocks. As soon as the pharmas started to drop and money started moving back into growth stocks, biotech fell right along with them. That's why I suggested affx might be moving down along with a shift away from defensive stocks. It's strange, because in a way biotech's are the furthest thing away from most defensives, but they ARE medical stocks, many of which are defensive. Anyway, I'm not sure what my point is, other than that when a real bull market starts, I hope people still remember affx is a growth stock first and foremost. just my 2 cents Brad